Mabwell (Shanghai) Bioscience Co., Ltd.

In March 2025, the US biosimilars market will celebrate ten years since the first biosimilar received approval from the US Food and Drug Administration, under the Biologics Price Competition and Innov

Corbus Pharmaceuticals is continuing a share price growth streak as investors warm to its plans for an antibody drug conjugate (ADC) to compete with Pfizer and an obesity drug to rival Novo Nordis

Chinese drug makers have made both major cuts and additions to their R&D pipelines in recent months, including for antibody-drug conjugates (ADCs) amid increasingly fierce competition, a Scrip revie

Mabwell ’s denosumab biosimilar MW032 has demonstrated similarity in efficacy to Amgen ’s Xgeva in solid tumor patients with bone metastasis. The Shanghai-based firm noted that this was the “first re